Design, synthesis, and biological evaluation of novel coxsackievirus B3 inhibitors

Bioorg Med Chem. 2010 Jun 15;18(12):4374-84. doi: 10.1016/j.bmc.2010.04.081. Epub 2010 Apr 29.

Abstract

The synthesis and SAR study of a novel class of coxsackievirus B3 (CVB3) inhibitors are reported. These compounds could be considered as the 6-chloropurines substituted at position 9 with variously substituted bicyclic scaffolds (bicyclo[2.2.1]heptane/ene-norbornane or norbornene). The synthesis and biological evaluation of 31 target compounds are described. Several of the analogues inhibited CVB3 in the low micromolar range (0.66-2muM). Minimal or no cytotoxicity was observed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / chemical synthesis*
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology
  • Bridged Bicyclo Compounds / chemical synthesis
  • Bridged Bicyclo Compounds / chemistry
  • Bridged Bicyclo Compounds / pharmacology
  • Chlorocebus aethiops
  • Drug Design
  • Enterovirus B, Human / drug effects*
  • Humans
  • Purines / chemical synthesis
  • Purines / chemistry*
  • Purines / pharmacology
  • Structure-Activity Relationship
  • Vero Cells

Substances

  • Antiviral Agents
  • Bridged Bicyclo Compounds
  • Purines
  • bicyclo(2.2.1)heptene
  • 6-chloropurine